Stock ETON ETON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Eton Pharmaceuticals, Inc.

Equities

ETON

US29772L1089

Real-time Estimate Cboe BZX
Other stock markets
 16:42:22 29/04/2024 BST 		5-day change 1st Jan Change
3.605 USD +4.49% Intraday chart for Eton Pharmaceuticals, Inc. +10.82% -17.77%
04-17 Eton Pharmaceuticals, Inc. cancelled the transaction announced on April 15, 2024 CI
04-15 Eton Pharmaceuticals, Inc. announced that it expects to receive $13.125 million in funding CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bourse Zurich: en rouge pour finir la semaine "banques centrales"
Sector Update: Health Care Stocks Steady Pre-Bell Friday
Sector Update: Health Care
Eton Pharmaceuticals Acquires U.S. Rights to PKU GOLIKE from Relief Therapeutics Holding SA
Eton Pharmaceuticals Acquires US Rights to Phenylketonuria Dietary Management Product
Relief Therapeutics trouve un partenaire de distribution US pour le Golike
Relief Therapeutics Grants Eton Pharmaceuticals Exclusive License for US Commercialization of Golike
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Eton Pharmaceuticals' ET-400 Protect Candidate Approved for US Patent
Eton Pharmaceuticals Awards U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
Eton Pharmaceuticals Says Nitisinone Capsules Now Commercially Available in US
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Eton Pharmaceuticals to Acquire Nitisinone Drug From Oakrum Pharma
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
Top Premarket Gainers
Eton Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Eton Pharmaceuticals, Inc. cancelled the acquisition of Certain assets including the Vistogard and Xuriden from Wellstat Therapeutics Corporation and Wellstat Biologics Corporation
Potential US Curbs on AI Chip Exports to China Drag Sentiment, Driving Premarket Losses for US Equity Futures
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ETON Stock
  4. News Eton Pharmaceuticals, Inc.
  5. Other languages